Premium
Levosimendan Interacts with Potassium Channel Blockers in Human Saphenous Veins
Author(s) -
Höhn József,
Pataricza János,
Petri András,
Tóth Gábor K.,
Balogh Ádám,
Varr András,
Papp Julius Gy.
Publication year - 2004
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/j.1742-7843.2004.pto940603.x
Subject(s) - iberiotoxin , levosimendan , glibenclamide , potassium channel , potassium , potassium channel blocker , calcium activated potassium channel , bk channel , chemistry , channel blocker , saphenous veins , pharmacology , medicine , anesthesia , vein , calcium , endocrinology , heart failure , organic chemistry , diabetes mellitus
The involvement of potassium channels in the venodilating capacity of the inodilator levosimendan in human saphenous vein preparations was investigated. Levosimendan caused relaxation with 50% effective concentration (EC 50 ) of 0.32±0.04 μM in isolated veins contracted by 5‐hydroxytryptamine. Fifteen μM glibenclamide, a blocker of the ATP‐sensitive potassium channels (K ATP ), partially inhibited the relaxing effect of the inodilator. In the presence of iberiotoxin, the selective blocker of large conductance calcium‐activated potassium channels (BK Ca ), levosimendan induced contraction with EC 50 of 0.21±0.06 μM. We presume that levosimendan dilates human saphenous veins by interacting with hyperpolarizing potassium channels (K ATP and BK Ca ).